The AJMC® Ophthalmology compendium is a comprehensive resource for clinical news and expert insights for treatment of disorders of the eye.
Dr Darius Moshfeghi Outlines the Impact of Delayed Treatment in ROPApril 17th 2023
Retinopathy of prematurity (ROP) that occurs in preterm babies can progress fast, which requires quick decisions early about treatment, explained Darius M. Moshfeghi, MD, chief, Retina Division, and professor at the Horngren Family Vitreoretinal Center, Byers Eye Institute, Department of Ophthalmology, Stanford University School of Medicine.
Treatments for DED Associated With MGD Require Future Evaluation, DevelopmentMarch 15th 2023
A systematic review found that there were currently a limited number of clinical trials evaluating treatment for dry eye disease (DED) that is associated with meibomian gland dysfunction (MGD).
Faster Rates of GCIPL, cpRNFL Thinning Associated With Higher Risks of GlaucomaMarch 9th 2023
Ganglion cell/inner plexiform layer (GCIPL) and circumpapillary retinal nerve fiber layer (cpRNFL) thinning were both associated with a higher risk of developing perimetric glaucoma.
Pegcetacoplan Approval a “Dream Come True” for Patients With Geographic Atrophy, Says Dr Eleonora LadMarch 5th 2023
Pegcetacoplan was approved by the FDA to treat geographic atrophy (GA), providing a treatment option for patients who previously had none, explained Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.
Faricimab: Mechanism of Action, Payers’ Perspective, and Real-World ExperienceFebruary 23rd 2023
Key opinion leaders discuss faricimab, its impact on the treatment landscape for wet AMD/DME, and what payers should look for when considering formulary positioning or utilization-management strategies.
Variability of Frequency Dosing for Anti-VEGF Agents in the Treatment of Wet AMDFebruary 23rd 2023
Dr Coney discusses the variability of frequency dosing with anti-VEGF therapy in patients with wet AMD and DME, and Dr Sheth expands on Ang-2 and its contribution to the development of vascular instability in wet AMD.
Anti-VEGF and Gene Therapy Impacting Wet AMD and DME Treatment LandscapesFebruary 16th 2023
Dr Sheth discusses his insights on anti-VEGF therapy that he has noticed in the treatment of wet AMD over the last decade, and Caesar Luo, MD, FASRS, FACS shares his insight on new treatment options and their impact on patient access and cost considerations.
Dr Michael Cohen Discusses Accessibility of Future Gene TherapiesFebruary 9th 2023
Michael N. Cohen, MD, FAAO, retinal surgeon at Wills Eye Hospital in Philadephia and Mid Atlantic Retina, speaks about the future of gene therapy and the accessibility and availability of these therapies moving forward.